160 related articles for article (PubMed ID: 18804806)
1. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
Serefoglu EC; Ozdemir AT; Balbay MD
J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
[No Abstract] [Full Text] [Related]
2. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
Atmaca AF; Balbay MD
J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
[No Abstract] [Full Text] [Related]
3. [The 20-core prostate biopsy protocol: a new gold standard?].
Irani J
Prog Urol; 2008 Apr; 18(4):251-2. PubMed ID: 18501306
[No Abstract] [Full Text] [Related]
4. Re: Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. K. Eichler, S. Hempel, J. Wilby, L. Myers, L. M. Bachmann and J. Kleijnen, J Urol, 175: 1605-1612, 2006.
Eskicorapci SY; Tuncay L
J Urol; 2006 Dec; 176(6 Pt 1):2745; author reply 2745-6. PubMed ID: 17085209
[No Abstract] [Full Text] [Related]
5. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132.
Eggener SE; Raman JD
J Urol; 2009 Jul; 182(1):396-7. PubMed ID: 19467675
[No Abstract] [Full Text] [Related]
6. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Thompson IM; Ankerst DP; Etzioni R; Wang T
J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
[No Abstract] [Full Text] [Related]
7. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
Stamatiou K; Alevizos A; Mariolis A; Sofras F
J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
[No Abstract] [Full Text] [Related]
8. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
9. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
10. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Singh A
Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
[No Abstract] [Full Text] [Related]
11. Editorial comment.
Chong KT
J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683273
[No Abstract] [Full Text] [Related]
12. Editorial comment.
Lin CC
J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683264
[No Abstract] [Full Text] [Related]
13. Editorial comment.
van Renterghem KM
J Urol; 2009 Oct; 182(4):1349; discussion 1349. PubMed ID: 19683263
[No Abstract] [Full Text] [Related]
14. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
Walsh PC
J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
[No Abstract] [Full Text] [Related]
15. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy.
Yokomizo Y; Miyoshi Y; Nakaigawa N; Makiyama K; Ogawa T; Yao M; Kubota Y; Uemura H
Urol Int; 2009; 82(3):280-5. PubMed ID: 19440014
[TBL] [Abstract][Full Text] [Related]
16. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
Connolly D; Hutton R; Keane PF
Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
[No Abstract] [Full Text] [Related]
17. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
Wagner MD; Daneshmand S; Sokoloff M; Barry JM
J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
[No Abstract] [Full Text] [Related]
18. Re: Noburu Numao, Satoru Kawakami, Minato Yokoyama et al. Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy. Eur urol 2007;52:1663-9.
Boscolo-Berto R; Galfano A; Iafrate M
Eur Urol; 2008 Aug; 54(2):469-70; author reply 471. PubMed ID: 18299171
[No Abstract] [Full Text] [Related]
19. Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.
Yoon DK; Park HS; Park JY
J Urol; 2010 Nov; 184(5):2214-5; author reply 2215. PubMed ID: 20864135
[No Abstract] [Full Text] [Related]
20. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
